The invertebrate and vertebrate Smad proteins have recently been identified as important mediators of the responses to transforming growth factor ␤ (TGF-␤) and related factors. We have previously shown that Smad3 and Smad4 (the product of the tumor suppressor gene DPC 4) strongly synergize as mediators of TGF-␤ signaling, and that inactive carboxy-terminally truncated mutants of either Smad act as dominant-negative inhibitors of the natural TGF-␤ response. The finding that Smad4, unlike Smad3, does not interact with the TGF-␤ receptor, coupled with the distinct structural features of Smad4, raises the possibility that Smad4 cooperates not only with Smad3, but also with Smad1 and Smad2 to mediate signaling by TGF-␤ family members.
Background
The transforming growth factor-␤ (TGF-␤) superfamily comprises various secreted polypeptides which regulate cell growth and differentiation and tissue morphogenesis in many organisms [1] . TGF-␤ and related factors, including activin and the bone morphogenetic proteins (BMPs), signal by interacting with two types of receptors that have serine/threonine kinase activity: type I and type II receptors, which form a heteromeric receptor complex [2, 3] . Recently, genetic approaches in Drosophila and Caenorhabditis elegans and complementary biochemical and developmental studies in vertebrates have resulted in the characterization of Mad (Mothers against Decapentaplegic) in Drosophila, Sma in C. elegans, and their vertebrate homologs Smads, as important signaling mediators of the response to TGF-␤-related factors [3, 4] . All Smads show conserved amino-terminal and carboxy-terminal domains, separated by a long proline-rich 'linker' segment of variable length and sequence [4] .
The results of studies in which Smad proteins were overexpressed have been used to suggest that different Smads induce distinct responses that mimic the natural receptormediated responses to different ligands. Xenopus Smad1 or human Smad1 are likely to be mediators of BMP-2/BMP-4 signals [5] [6] [7] , having similar roles to that of Mad in Decapentaplegic signaling [8] , whereas Smad2 may mediate activin signaling [5, 9] . We have shown previously that Smad3 and Smad4 (originally identified as the product of the candidate tumor suppressor gene DPC 4 [10] ) strongly synergize to induce TGF-␤-like responses, and function as mediators of TGF-␤ signaling [11] . Accordingly, inactive carboxy-terminal truncation mutants of either Smad3 or Smad4 can block natural TGF-␤ responses, indicating that both proteins are required for TGF-␤ signaling. In contrast to Smad3, however, Smad4 does not associate with the TGF-␤ receptor complex and is not phosphorylated, suggesting that Smad4 functions differently from Smad3 and might act downstream from Smad3. The amino-acid sequences of the Smads also indicate that Smad4 is quite distinct, having a characteristic insert in the conserved carboxy-terminal domain and a considerably larger size than Smad1, Smad2 and Smad3, which are more closely related to each other. The cooperativity of Smad4 with Smad3, its distinct structure, and its lack of receptor association raise the possibility that Smad4 may also cooperate with Smad1 and Smad2 to mediate signaling by BMP-2/BMP-4 or activin, respectively; in this way, Smad4 may function as a common mediator of signaling by TGF-␤-related factors.
Results and discussion

Smad4/DPC 4 synergizes with Smad1 and Smad2
If Smad4 cooperates with Smad1 or Smad2, then we would predict that Smad4 synergizes with Smad1 to induce a BMP-2/BMP-4-like response, and with Smad2 to induce an activin-like response, by analogy to the observed synergy of Smad4 with Smad3 to induce a TGF-␤-like response [11] . We tested this hypothesis by using the Xenopus 'animal cap' assay in which a piece of animal pole explant, capable of responding to an inducing signal by developing into mesoderm, is cultured with potential inducing factors and the resulting tissue analyzed. Consistent with previous findings [5, 7, 9, 12] , microinjection of mRNA encoding either BMP-4 or Smad1 induced ventral mesoderm, as assessed by the induction of globin mRNA expression (Fig. 1a) . In contrast, treatment of the animal caps with activin or injection of Smad2 mRNA induced muscle actin mRNA expression, a marker of dorsal mesoderm (Fig. 1a) . If Smad4 synergizes with endogenous Smad1 and Smad2 to mediate ligand-independent BMP-2/BMP-4 and activin signaling, then injection of Smad4 mRNA would be expected to induce both ventral and dorsal mesoderm. This was indeed the case, as injection of Smad4 mRNA induced expression of both the ventral mesoderm marker globin and the dorsal mesoderm marker muscle actin in Xenopus animal cap assays (Fig. 1a) . Thus, Smad4 induced both ventral and dorsal mesoderm, mimicking the effects of BMP-2/BMP-4 and activin/TGF-␤.
We also injected small amounts of Smad1 or Smad4 mRNA, or both of them together. As shown in Figure 1b , each of the injected mRNAs by itself was not sufficient to induce considerable expression of the ventral mesoderm marker globin. When injected together, however, they acted synergistically to strongly induce globin expression. Similarly, when compared to the effects of Smad2 or Smad4 mRNA alone, it could be seen that low levels of Smad2 and Smad4 mRNA also synergized to induce increased expression of muscle actin, a marker of dorsal mesoderm differentiation (Fig. 1b) .
To further evaluate the cooperativity of Smad4 with Smad1, Smad2 and Smad3, we tested the ability of the Smads to induce luciferase expression from the promoter for plasminogen activator inhibitor-1 (PAI-1). We have previously shown that Smad3 and Smad4 each induce a low level of luciferase expression in the PAI-1 luciferase assay, and that they dramatically synergize to induce a 20-fold to 30-fold increase in luciferase expression (Fig.  2) [11] . Similarly, Smad4 coexpression with Smad2 resulted in a strong synergy in inducing luciferase expression, although Smad2 by itself did not induce detectable expression. Coexpression of Smad1 and EF-1␣ mRNA is ubiquitously expressed and serves as a control for the quantity of mRNA in each assay. Uninjected animal caps were also tested in each case (labeled 'control'), and the positive control (embryo) corresponds to whole embryo RNA; the negative control (-RT) corresponds to embryonic RNA subjected to RT-PCR without the addition of reverse transcriptase. Smad4 did not induce a luciferase response, consistent with the lack of sensitivity of this reporter assay to BMP-2/BMP-4 ( Fig. 2) .
The biological activities of Smad3 and Smad4 require their conserved carboxy-terminal domains
In order to determine which domains are required for synergy between Smads, we constructed expression plasmids for the segments of Smad3 and Smad4 shown in Figure 3a . Western blot analyses of transfected cell lysates revealed that these Smad3 and Smad4 segments, as well as the full-size proteins, were stably expressed (Fig. 3c ).
Using the PAI-1 luciferase construct as a reporter system, we found that the synergy between Smad3 and Smad4 was associated with the conserved carboxy-terminal domains of both Smads (Fig. 3b ). We have also recently shown that these carboxy-terminal domains mediate homomeric and heteromeric interactions of Smad3 and Smad4 [13] . Thus, coexpression of Smad4 with the carboxy-terminal domain of Smad3, with or without Smad3's proline-rich linker segment, resulted in a similar synergistic response to that obtained with full-size Smad3 and Smad4 (Fig. 3b , lanes 7 and 8). This result is consistent with the ability of the Smad2 carboxy-terminal domain to induce dorsal mesoderm, although in the animal cap assay the response obtained with the carboxyl terminus exceeded the response with full-size Smad2 [9] . The same carboxy-terminal domain in Smad1 also displays transcriptional activity when fused to a GAL4 binding domain that allows association with DNA [7] .
Conversely, the carboxy-terminal domain of Smad4, with the Smad4 proline-rich linker sequence, also synergized with full-size Smad3 (Fig. 3b , lane 11), further confirming that the signaling activity of Smads is associated with their conserved carboxy-terminal domains. However, coexpression of full-size Smad3 and the carboxy-terminal domain of Smad4 without its proline-rich linker (Smad4C294) resulted in a very low activity (Fig. 3b , lane 13). It has been reported that the carboxy-terminal domain of Smad4 is constitutively active in a transcription assay when fused to a GAL4 DNA-binding domain [7] . As the truncated Smad4 domain used in the transcription assay extends 28 amino acids further at its amino terminus than Smad4C294, we designed another variant of the Smad4 carboxy-terminal domain, Smad4C266, which is identical to the truncated Smad4 domain that was used in the transcription assay [7] . In contrast to Smad4C294, Smad4C266 strongly synergized with full-size Smad3 in the PAI-1 luciferase assay (Fig. 3b, lane 12 ). This result indicates that the 28 additional amino acids that are not incorporated in Smad4C294 are required for the synergistic activity of Smad4 with Smad3. It is indeed possible that they play a role in stabilizing the homomeric interactions of Smad4 or the heteromeric interactions with Smad3, as both homomeric and heteromeric interactions between Smad3 and Smad4 are required for full biological activity [13] .
Remarkably, coexpression of the carboxy-terminal domains of Smad3 and Smad4, with or without their proline-rich upstream sequences, did not result in luciferase expression (Fig. 3b, lanes 14 and 15) , suggesting that sequences in the amino-terminal conserved domains are required for the activity of the carboxy-terminal domains or for the homomeric and heteromeric interactions. Taken together, these findings also suggest that the ability of the Smad2 carboxy-terminal domain to induce dorsal mesoderm in Xenopus animal caps [9] may be due to an interaction with endogenous Smad4. 
Role of the Smad4 carboxyl terminus in nuclear translocation
The proposed role of Smads as transcriptional mediators is consistent with their localization to the nucleus. Indeed, Smads have been localized by immunofluorescence to both the cytoplasm and the nucleus, and the fraction of Smad proteins in the nucleus can be increased by signaling through their associated receptors [6, 7, 9] . We thus evaluated the nuclear localization of all four Smad proteins in transfected COS-1 cells using immunofluorescence. Smad1 and Smad2 were distributed in both the cytoplasm and nucleus of transfected cells (Fig. 4a,b) , consistent with previous findings [6, 7, 9] , whereas Smad3 and Smad4 were predominantly localized to the nucleus (Fig. 4c,d ). Treatment of Smad3-or Smad4-overexpressing cells with TGF-␤, activin or BMP-2, or coexpression with a constitutively active Thr204→Asp mutant of the type I TGF-␤ receptor, did not affect nuclear localization (data not shown).
We next examined the subcellular localization of different Smad proteins with short carboxy-terminal truncations. A carboxy-terminal truncation of only 39 amino acids inactivates Mad function in Drosophila [14] , and the corresponding mutation has been found in the Smad4/DPC 4 gene in pancreatic carcinomas where it is thought to inactivate the tumor suppressor function of Smad4/DPC 4 [10] . Similar deletions in Smad3 and Smad4 not only inactivate them but also confer dominant-negative interference with the endogenous Smad activity required for TGF-␤ signaling [11] . As shown in Figure 4e -g, there was no detectable effect of these short carboxy-terminal truncations of Smad1, Smad2 and Smad3 on their subcellular localization. Surprisingly, the same carboxy-terminal deletion prevented nuclear localization of Smad4: the Smad4∆c mutant was localized in the cytoplasm without any detectable immunofluorescence in the nucleus (Fig. 4h) . The inability of Smad4∆c to translocate into the nucleus distinguishes Smad4 from Smad1, Smad2 and Smad3. Remarkably, the carboxy-terminal deleted sequence does not contain a recognizable nuclear translocation signal [15] .
As the carboxy-terminally truncated form of Smad4 functions as a dominant-negative inhibitor of TGF-␤ signaling, and considering the functional cooperativity and heteromeric physical affinity between Smad4 and Smad1, Smad2 and Smad3 [13] , we evaluated whether coexpression of Smad4⌬c would affect the subcellular localization of full-size Smad1, Smad2 and Smad3. As shown in Figure  4i -l, overexpression of Smad4⌬c prevented nuclear localization of wild-type Smad1, Smad2, Smad3 and Smad4. In Smad4⌬c-producing cells, a coexpressed immunotagged cyclin B1 with an attached nuclear localization sequence was appropriately translocated into the nucleus (data not shown). These findings provide additional evidence for the functional cooperation of Smad4 with Smad1, Smad2
and Smad3, and strongly support a physical heteromeric interactions between Smad4⌬c with these full-size Smad proteins. Such interactions would be consistent with the heteromeric and homomeric associations observed in yeast two-hybrid assays [11, 13] . Accordingly, immunoprecipitation of Smad1, Smad2, Smad3 or Smad4 resulted in coprecipitation of coexpressed Smad4⌬c in transfected COS-1 cells (Fig. 4m-o) .
The observed ability of the mutant Smad4, as a result of its short carboxy-terminal deletion, to prevent nuclear translocation of Smad1, Smad2 and Smad3, and the physical heteromeric interaction between Smad4⌬c and these Smads may explain the potent ability of Smad4⌬c to function as a dominant-negative mutant. This same deletion also inactivates the function of Smad4/DPC 4 as a suppressor of pancreatic carcinomas [10] . Because Smad3⌬c is still able to translocate into the nucleus, yet acts as a dominant-negative Expressing Myc-tagged Smad4 resulted in the appearance of a low molecular weight immunoreactive band as well as the full-size protein (seen in n), which is presumably a degradation product.
inhibitor of Smad activity and TGF-␤ signaling [11] , it may act through a different mechanism to inhibit TGF-␤ signaling.
The ability of both the full-size and the carboxy-terminal truncated forms of Smad1, Smad2 and Smad3 to translocate into the nucleus is in striking contrast to the behavior of Smad4, and raises the possibility that a second nuclear translocation sequence or motif may be located upstream of the conserved carboxy-terminal domain in Smad1, Smad2 and Smad3. We therefore assessed, by immunofluorescence, the ability of the carboxy-terminal domain of Smad3, with or without the short carboxy-terminal deletion, as well as the ability of several other Smad3 truncation mutants (see Fig. 3a ) to localize to the nucleus. As shown in Figure  5d , the conserved carboxy-terminal segment of Smad3, expressed by itself, translocated into the nucleus of transfected cells. In contrast, the same conserved domain containing the carboxy-terminal 43 amino-acid deletion was not able to translocate into the nucleus (Fig. 5e ). This result, and the inability of Smad4⌬c to translocate into the nucleus, suggests that the conserved carboxy-terminal domains of the Smads may contain an as yet unidentified nuclear localization sequence, and that Smad3, and presumably Smad1 and Smad2 but not Smad4, contain a second nuclear localization sequence upstream from the conserved carboxy-terminal domain. This second nuclear localization sequence is most likely to be located in the proline-rich linker region, as the amino-terminal domain of Smad3 with the Smad3 linker sequence, but not the amino-terminal domain alone, translocated into the nucleus (Fig. 5a,b) .
Taken together, our current findings provide evidence for a function of Smad4 as a common mediator of Smad activity and receptor signaling by TGF-␤-related factors.
In contrast to Smad1, Smad2 and Smad3 which are phosphorylated and may be direct substrates for the receptors' kinase activity [6, 11, 16] , Smad4 is not phosphorylated or receptor-associated. Smad4 cooperates functionally with Smad1, Smad2 and Smad3, as illustrated by its synergistic activity with these Smads and the ability of Smad4⌬c to block their nuclear translocation. Furthermore, the role of the short carboxy-terminal sequence of Smad4 in nuclear translocation is remarkable, especially as deleting the corresponding sequences in Smad1, Smad2 and Smad3 does not interfere with their nuclear translocation. This suggests the presence of an additional upstream nuclear translocation sequence or motif in these Smads, which is likely to be located in the linker domain. Further studies will be required to characterize the structural requirements, and to identify the mechanism of nuclear translocation, of Smad4 as well as of the other Smad proteins.
Following submission of this manuscript, Lagna et al. [17] also showed that Smad4/DPC 4 cooperates with Smad1 and Smad2 in Xenopus animal cap assays and synergizes with Smad2 in an assay for gene induction using 3TP-lux as a reporter. Their findings and ours are in agreement.
Materials and methods
Plasmids
The mammalian expression plasmids for wild-type Smad1, Smad2, Smad3 and Smad4 and the carboxy-terminal truncated mutants Smad1⌬c, Smad2⌬c, Smad3⌬c and Smad4⌬c have been described previously [11] . DNA fragments for defined Smad segments were generated by PCR amplification and flanked with 5′ EcoRI or BamHI and 3′ SalI sites, and subsequently subcloned into the pRK5F plasmid [18] , thereby introducing a carboxy-terminal FLAG tag to the expressed proteins. Detailed descriptions of how the individual expression plasmids for the various Smad mutants were generated can be obtained upon request. 
Embryonic mesoderm induction assays
Plasmids of the vector pRK5 containing the full-size coding sequences for Smad1, Smad2 or Smad4 [11] or for BMP-4 (unpublished) were linearized with PvuI. Capped mRNA was synthesized from the sp6 promoter using the SP6 mMessage Machine kit (Ambion). Xenopus embryo animal caps were injected at the 2-cell stage, cut at blastula stage 8 to early 9 and cultured to late stage 32. Recombinant human activin A (Lot #15365-36(1)) was obtained through NHPP, NIDDK, NICHHD, US Drug Administration. RNA was prepared from five caps or one embryo using Trizol (Life Technologies, Inc.). Globin (ventral mesoderm), muscle actin (dorsal mesoderm), N-CAM (neural tissue) and EF-1␣ (control) mRNAs were assayed by RT-PCR and subsequent gel electrophoresis of the 32 P-labelled PCR products. The RT-PCR conditions and primer sequences were as described [19, 20] .
Transient transfections, immuoprecipitations and immunoblotting
Both 293 and SW480.7 cells, maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (FBS), were transfected using LipfectAMINE (Life Technologies, Inc.) according to the manufacturer's suggestion. Cells were lysed 48 h after transfection in a lysis buffer (25 mM Tris pH 8.0, 300 mM NaCl, 1% Triton X-100) and immunoprecipitations were done as described using the anti-FLAG M2 antibody (IBI, Kodak) or anti-Myc 9E2 antibody (J.M. Bishop, UCSF). Imunoblotting using these antibodies was performed using the ECL kit (Amersham).
Gene expression reporter assay
TGF-␤-inducible and activin-inducible transcription from the PAI-1 promoter in plasmid p800luc [21] was assayed as described [18] . Plasmid pRK␤gal, which expresses ␤-galactosidase under control of the CMV promoter [18] , was included in all assays to normalize the luciferase activities for transfection efficiency. Briefly, transfection of SW480.7 cells was carried out in six-well dishes using LipofectAMINE. For each assay, 1 g expression plasmid (0.5 g of a Smad expression plasmid, supplemented with 0.5 g pRK5 vector plasmid for single transfections, 0.5 g p800luc and 0.5 g pRK␤gal were cotransfected. Cells were treated with or without 5 ng ml -1 TGF-␤1 or 12.5 ng ml -1 activin A in medium containing 0.2% FBS, 12 h after transfection. After 24 h, the cells were lysed and luciferase activity was measured.
Immunofluorescence COS-1 cells were transiently transfected with 0.5-1.0 g of an expression plasmid for a wild-type Smad or with 5 g of an expression plasmid encoding a truncated Smad using LipofectAMINE. Cells were plated onto Falcon 8 chamber culture slides 24 h after transfection and incubated overnight. Immunofluorescence was performed using anti-FLAG antibody M2 (1:500 dilution, IBI Kodak) and FITC-conjugated goat antimouse IgG antibody (1:200 dilution, Jackson Immunological Laboratory).
